{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:45:31Z","timestamp":1767134731156,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":61,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006254","type":"reference-entry","created":{"date-parts":[[2006,10,20]],"date-time":"2006-10-20T00:02:14Z","timestamp":1161302534000},"source":"Crossref","is-referenced-by-count":17,"title":["Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients"],"prefix":"10.1002","author":[{"given":"Giovanni FM","family":"Strippoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grahame J","family":"Elder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,10,18]]},"reference":[{"issue":"15","key":"10.1002\/14651858.CD006254-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006254-BIB2|cit2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1046\/j.1523-1755.2000.00183.x","article-title":"A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism","volume":"58","author":"Goodman","year":"2000","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD006254-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1681\/ASN.V1341017","article-title":"The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism","volume":"13","author":"Goodman","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/j.ajkd.2004.08.029","article-title":"Pharmacokinetics, pharmacodynamics and safety of cinacalcet hydrochloride in hemodialysis patients at doses up to 200 mg once daily","volume":"44","author":"Harris","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006254-BIB5|cit5","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1046\/j.1523-1755.2003.00720.x","article-title":"The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism","volume":"63","author":"Lindberg","year":"2003","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD006254-BIB6|cit6","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254-BIB7|cit7","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"218","article-title":"Cinacalcet HCl reduces bone turnover and bone marrow fibrosis in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract]","author":"Malluche","year":"2004"},{"issue":"3","key":"10.1002\/14651858.CD006254-BIB8|cit8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/01.ASN.0000050224.03126.AD","article-title":"The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease","volume":"14","author":"Quarles","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD006254-BIB9|cit9","first-page":"460A","article-title":"Cinacalcet HCl is an effective treatment for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) not yet receiving dialysis [abstract]","volume":"14","author":"Coburn","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006254-BIB10|cit10","first-page":"150","article-title":"Sustained, long-term reductions in parathyroid hormone (iPTH) after 3 years of treatment with calcimimetic cincalcet HCl in patients with secondary hyperparathyroidism (SPTH) [abstract]","volume":"18","author":"Cunningham","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD006254-BIB11|cit11","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"219","article-title":"The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalisation, and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]","author":"Cunningham","year":"2004"},{"key":"10.1002\/14651858.CD006254-BIB12|cit12","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"319","article-title":"Greater achievement of NKF-K\/DOQI bone metabolism and disease targets with oral cinacalcet HCL in an EU\/Australian phase 3 study in haemodialysis subjects [abstract]","author":"Francisco","year":"2004"},{"key":"10.1002\/14651858.CD006254-BIB13|cit13","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"319","article-title":"Cinacalcet HCL reduces parathyroid hormone (PTH) and calcium-phosphate product (Ca x P) regardless of concurrent changes in vitamin D adminstration [abstract]","author":"Fournier","year":"2004"},{"key":"10.1002\/14651858.CD006254-BIB14|cit14","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"219","article-title":"Cinacalcet HCl effectively reduces intact parathyroid hormone (iPTH) and ca x p irrespective of the severity of sevondary hyperparathyroidism (HPT)","author":"Frazao","year":"2004"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD006254-BIB15|cit15","first-page":"460A","article-title":"Cinacalcet HCl is an effective primary therapy for the management of secondary hyperparathyroidism [abstract]","volume":"14","author":"Goodman","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD006254-BIB16|cit16","first-page":"462A","article-title":"Control of bio-intact parathyroid hormone (PTH) elvels with the calcimimetic Cinacalcet HCl in hemodialysis patients with secondary hyperparathyroidism (HPT) [abstract]","volume":"14","author":"Martin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program and Abs","key":"10.1002\/14651858.CD006254-BIB17|cit17","first-page":"463A","article-title":"Cinacalcet HCl controls secondary hyperparathyroidism (HPT) in dialysis patients regardless of disease severity [abstract]","volume":"14","author":"Quarles","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254-BIB18|cit18","first-page":"275A","article-title":"Long-term treatment of secondary hyperparathyroidism (HPT) with cincalcet (Sensipar) in patients receiving dialysis [abstract]","volume":"15","author":"Sterrett","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254-BIB19|cit19","first-page":"280A","article-title":"The CONTROL STUDY: enhanced achievement of NKF-K\/DOQI bone metabolism and disease targets using cinacalcet HCL (Sensipar) [abstract]","volume":"15","author":"Reed","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD006254-BIB20|cit20","first-page":"863A","article-title":"Preliminary results from TARGET: treatment strategies to achieve recommended K\/DOQI goals in ESRD patients on Cinacalcet [abstract]","volume":"15","author":"Chertow","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB21|cit21","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00003495-200363060-00005","article-title":"Hyperphosphataemia in renal failure: causes, consequences and current management","volume":"63","author":"Albaaj","year":"2003","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006254-BIB22|cit22","unstructured":"Australia New Zealand Dialysis Transplant Registry (ANZDATA) ANZDATA 27th Annual Report http:\/\/www.anzdata.org.au\/anzdata\/AnzdataReport\/download.htm"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB23|cit23","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0272-6386(96)90396-0","article-title":"Enrollment parathyroid hormone level is a new marker of survival in hemodialysis and peritoneal dialysis therapy for uremia","volume":"28","author":"Avram","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD006254-BIB24|cit24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJM199808273390903","article-title":"The effects of normal, as compared with low, hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin","volume":"339","author":"Besarab","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD006254-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD006254-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1600-6143.2004.00583.x","article-title":"Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation","volume":"4","author":"Borrows","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD006254-BIB27|cit27","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006254-BIB28|cit28","unstructured":"CARI Guidelines http:\/\/www.kidney.org.au\/cari\/guidelines.php"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB29|cit29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1681\/ASN.V86965","article-title":"Lower probability of patient survival with continuous peritoneal dialyssi in the united states compared with canada. Canada-USA (CANUSA) Peritoneal dialysis study group","volume":"8","author":"Churchill","year":"1997","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8-9","key":"10.1002\/14651858.CD006254-BIB30|cit30","first-page":"327","article-title":"Surgical treatment of secondary hyperparathyroidism in chronic kidney failure. Results of total parathyroidectomy with parathyroid autotransplantation","volume":"130","author":"Courant","year":"1993","journal-title":"Journal de Chirurgie"},{"key":"10.1002\/14651858.CD006254-BIB31|cit31","series-title":"41st ERA-EDTA Congress; 2004; May 15-18; Lisbon (Portugal)","first-page":"219","article-title":"The effect of cinacalcet HCl on parathyroidectomy, fracture, hospitalization and mortality in dialysis subjects with secondary hyperparathyroidism (HPT) [abstract]","author":"Cunningham","year":"2004"},{"issue":"6964","key":"10.1002\/14651858.CD006254-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"issue":"7124","key":"10.1002\/14651858.CD006254-BIB33|cit33","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/bmj.316.7124.61","article-title":"Bias in location and selection of studies","volume":"316","author":"Egger","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006254-BIB34|cit34","unstructured":"US Food Drug Administration Sensipar (cinacalcet HCl) tablets http:\/\/www.fda.gov\/cder\/foi\/label\/2004\/21688_Sensipar_lbl.pdf"},{"issue":"10","key":"10.1002\/14651858.CD006254-BIB35|cit35","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patient","volume":"12","author":"Ganesh","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7414","key":"10.1002\/14651858.CD006254-BIB36|cit36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD006254-BIB37|cit37","first-page":"622","article-title":"Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease","volume":"26","author":"Hutchison","year":"1995","journal-title":"Kidney international"},{"issue":"7384","key":"10.1002\/14651858.CD006254-BIB38|cit38","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bmj.326.7384.334","article-title":"Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity [letter]","volume":"326","author":"Juni","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006254-BIB39|cit39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1681\/ASN.2004070602","article-title":"Serum phosphate levels and mortality risk among people with chronic kidney disease","volume":"16","author":"Kestenbaum","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD006254-BIB40|cit40","series-title":"Fourth International Cochrane Colloquium; 1996 Oct 20-24; Adelaide (Australia)","article-title":"Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE","author":"Lefebvre","year":"1996"},{"issue":"8","key":"10.1002\/14651858.CD006254-BIB41|cit41","first-page":"459","article-title":"Breast cancer trial with erythropoietin terminated unexpectedly","volume":"4","year":"2004","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006254-BIB42|cit42","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ndt\/gfh1002","article-title":"The importance of bone health in end-stage renal disease: out of the frying pan, into the fire?","volume":"19 Suppl 1","author":"Malluche","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"85","key":"10.1002\/14651858.CD006254-BIB43|cit43","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1046\/j.1523-1755.63.s85.26.x","article-title":"Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population","author":"Marco","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"3","key":"10.1002\/14651858.CD006254-BIB44|cit44","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2003.12.003","article-title":"Diagnosis, assessment and treatment of bone turnover abnormalities in renal osteodystrophy","volume":"43","author":"Martin","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/01.ASN.0000130566.69170.5E","article-title":"Development, prevention and potential reversal of left ventricular hypertrophy in chronic kidney disease","volume":"15","author":"McMahon","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"15","key":"10.1002\/14651858.CD006254-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT Statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"issue":"4 Suppl 3","key":"10.1002\/14651858.CD006254-BIB47|cit47","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006254-BIB48|cit48","first-page":"1080","article-title":"Calcimimetics--new drugs with the potential to control hyperparathyroidism","volume":"83","author":"Ott","year":"1998","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD006254-BIB49|cit49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/jama.282.8.786","article-title":"Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease","volume":"282","author":"Psaty","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD006254-BIB50|cit50","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0272-6386(95)90599-5","article-title":"Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis","volume":"26","author":"Qi","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006254-BIB51|cit51","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD006254-BIB52|cit52","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1046\/j.1523-1755.2003_t01-1-00783.x","article-title":"Calcimimetics in action","volume":"53","author":"Sherrard","year":"1998","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD006254-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.1986.4.10.1529","article-title":"Publication bias: the case for an international registry of clinical trials","volume":"4","author":"Simes","year":"1986","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD006254-BIB54|cit54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.semnephrol.2003.08.013","article-title":"Osteoporosis and chronic kidney disease","volume":"24","author":"Stehman-Breen","year":"2004","journal-title":"Seminars in Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD006254-BIB55|cit55","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/01.ASN.0000113243.24155.2F","article-title":"Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes","volume":"15","author":"Stevens","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD006254-BIB56|cit56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.282.8.790","article-title":"Are surrogate markers adequate to assess cardiovascular disease drugs?","volume":"282","author":"Temple","year":"1999","journal-title":"JAMA"},{"issue":"85","key":"10.1002\/14651858.CD006254-BIB57|cit57","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1523-1755.63.s85.22.x","article-title":"Calcimimetic agents: review and perspectives","author":"Urena","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"5","key":"10.1002\/14651858.CD006254-BIB58|cit58","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/0272-6386(95)90453-0","article-title":"Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity","volume":"26","author":"Wang","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"5 Suppl 3","key":"10.1002\/14651858.CD006254-BIB59|cit59","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0272-6386(04)01103-5","article-title":"Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the dialysis outcomes and practice patterns study (DOPPS)","volume":"44","author":"Young","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD006254-BIB60|cit60","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/j.1651-2227.2000.tb00361.x","article-title":"Bone biopsy results and serum bone turnever parameters in uremic children","volume":"89","author":"Ziolkowska","year":"2000","journal-title":"Acta Paediatrica"},{"issue":"5","key":"10.1002\/14651858.CD006254-BIB61|cit61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.ajkd.2006.01.015","article-title":"Meta-analysis of biochemical and patient-level effects of calcimimetic therapy","volume":"47","author":"Strippoli","year":"2006","journal-title":"American Journal of Kidney Diseases"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006254.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006254\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:57:01Z","timestamp":1628531821000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006254"}},"subtitle":[],"editor":[{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2006,10,18]]},"references-count":61,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006254","relation":{},"subject":[],"published":{"date-parts":[[2006,10,18]]}}}